Moderna, Inc. (MRNA)

NASDAQ: MRNA · IEX Real-Time Price · USD
182.94
-3.90 (-2.09%)
At close: Aug 8, 2022 4:00 PM
178.69
-4.25 (-2.32%)
After-hours: Aug 8, 2022 6:30 PM EDT
-2.09%
Market Cap 71.57B
Revenue (ttm) 23.00B
Net Income (ttm) 14.06B
Shares Out 391.20M
EPS (ttm) 31.60
PE Ratio 5.79
Forward PE 7.49
Dividend n/a
Ex-Dividend Date n/a
Volume 3,987,596
Open 185.20
Previous Close 186.84
Day's Range 180.09 - 190.28
52-Week Range 115.61 - 497.49
Beta 1.60
Analysts Buy
Price Target 225.08 (+23.0%)
Earnings Date Aug 3, 2022

About MRNA

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus... [Read more...]

Industry Biotechnology
IPO Date Dec 7, 2018
CEO Stephane Bancel
Employees 3,400
Stock Exchange NASDAQ
Ticker Symbol MRNA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 26 analysts, the average rating for MRNA stock is "Buy." The 12-month stock price forecast is 225.08, which is an increase of 23.03% from the latest price.

Price Target
$225.08
(23.03% upside)
Analyst Consensus: Buy
Stock Forecasts

News

MRNA vs. TECH: Which Stock Should Value Investors Buy Now?

MRNA vs. TECH: Which Stock Is the Better Value Option?

Other symbols: TECH

COVID vaccine manufacturer Moderna's CEO discusses the company's Q3 earnings

Moderna CEO Stéphane Bancel discusses the reasons behind the company's Q3 success, and his anticipations for Q4. Segment originally aired on August 3, 2022.

Prediction: This Bear Market Will Test Your Resolve In (At Least) 3 Ways

Your portfolio is counting on you to pass the tests.

Where Will Moderna Be in 1 Year?

The biotech's fortunes could reverse.

Moderna CEO discusses COVID-19 risks, vaccine boosters, MRNA technology and more

Moderna CEO Stéphane Bancel sat down with Yahoo Finance's Anjalee Khemlani to discuss what's been happening with their covid booster, meeting global vaccine demand, and what other medical areas the comp...

Moderna Q2 Earnings, Buyback Plans Lift Biotech ETFs

Moderna Inc (NasdaqGS: MRNA) shares surged Wednesday, lifting biotechnology sector-related exchange traded funds, after the pharmaceutical company revealed better-than-expected profit and revenue in its...

Other symbols: BBHGERMIBBQ

Tech Stocks Surging: 5 Stocks Sending the Nasdaq Higher on Wednesday

A combination of solid earnings and investor optimism has many of the year's losers seeing some gains.

Other symbols: MELIMETAOKTAPYPL

4 Stocks With High Return on Equity

When a company's return on equity ratio is superior to most of its competitors, it generally indicates the company has been very efficient in generating profits. Thus, investors may want to consider the...

Other symbols: DVNPFETSLA

Moderna (MRNA) Beats on Q2 Earnings, Starts $3B Buyback Program

Moderna's (MRNA) earnings and sales beat expectations. The company also announces another $3-billion buyback program.

Moderna CEO: ‘We are seeing very strong' vaccine demand

Moderna CEO Stéphane Bancel speaks with Yahoo Finance's Anjalee Khemlani about earnings, COVID-19 vaccine demand, the biotech company's pipeline, and monkeypox vaccine development.nce

Moderna Just Gave Investors 499 Million Reasons to Worry

Investors are cheering the company's Q2 results. But there was a troubling detail in Moderna's update.

Moderna stock gets boost from earnings beat, COVID-19 vaccine sales

Yahoo Finance's Anjalee Khemlani discusses second-quarter earnings for Moderna, the Biden administration's fall booster campaign, COVID-19 vaccine sales, and longer-term vaccine growth.

Moderna (MRNA) Stock Pops on Strong Sales, Earnings Beat

MRNA) research Coronavirus (Covid 19) vaccine. Row of vaccine bottles with blurred Moderna company logo on background.

Moderna (MRNA) Q2 Earnings and Revenues Beat Estimates

Moderna (MRNA) delivered earnings and revenue surprises of 16.44% and 22.08%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Moderna Stock Surges After Covid Vaccine Sales Obliterate Expectations

Moderna stock jumped Wednesday after sales of the company's Covid vaccine and earnings easily outperformed expectations. The post Moderna Stock Surges After Covid Vaccine Sales Obliterate Expectations a...

Moderna's 2Q earnings beat expectations, but it writes off $500 million in expiring Covid shots

Moderna took a nearly $500 million hit on write-downs for vaccine inventory that has expired or is expected to expire before is can be used.

Moderna's stock rises 3% after beating earnings expectations in the second quarter

Shares of Moderna Inc. MRNA, -0.43% gained 3.8% in premarket trading on Wednesday after the company beat earnings and revenue expectations in the second quarter of the year. Moderna had net income of $2...

Moderna retains COVID vaccine sales view on weak demand from low-income nations

Moderna Inc on Wednesday maintained its full-year sales outlook for its COVID-19 vaccine, following a similar prediction by bigger rival Pfizer Inc a week ago, amid tepid demand from low-to-middle incom...

Moderna Reports Second Quarter 2022 Financial Results and Provides Business Updates

Second quarter 2022 revenues of $4.7 billion; GAAP net income of $2.2 billion and GAAP diluted EPS of $5.24 Company reiterates advance purchase agreements for expected delivery in 2022 of approximately ...

3 Health Care Stocks in Great Financial Health

Health care's potential to do better in both up and down markets makes it a valuable part of a long-term investment strategy.

Other symbols: CVSPFE

Could the Fall Booster Market Boost Vaccine Stocks?

The booster market might be a long-term source of revenue.

Other symbols: BNTXNVAX

Why Pfizer and BioNTech Are Beating Moderna in the Omicron Booster Market

Moderna is still prevailing in the omicron booster market in at least one important way.

Other symbols: BNTXPFE

Products Are in, Platforms Are Out for Biotech Investors

Platforms are out.

Could This News Change Everything for Moderna?

Moderna's blockbuster product is set for a new wave of demand.

Why Moderna Was a Stock Market Star on Friday

The biotech keeps up a steady supply of coronavirus vaccine boosters to a very reliable customer.